A B S T R A C T

Background
High blood pressure during pregnancy is a common cause of serious morbidity and death. Calcium supplementation may reduce the risk of high blood pressure through a number of mechanisms and may help to prevent preterm labour.
Objectives
To assess the effects of calcium supplementation during pregnancy on hypertensive disorders of pregnancy and related maternal and child adverse outcomes.
Search strategy
We searched the Cochrane Pregnancy and Childbirth Group trials register (September 2003) and the Cochrane Central Register of Controlled Trials (Issue 3, 2003) . We contacted study authors.
Selection criteria
Randomised trials comparing at least one gram daily of calcium during pregnancy with placebo.
Data collection and analysis
Eligibility and trial quality were assessed. Data extraction was carried out and double entered.
Main results
Eleven studies were included, all of good quality. There was a reduction in the incidence of high blood pressure with calcium supplementation (10 trials, 6634 women: relative risk (RR) random effects model 0.58, 95% confidence intervals (CI) 0.43 to 0.79). The effect was greater amongst women at high risk of developing hypertension (four trials, 327 women: RR 0.47, 95% CI 0.22 to 0.97), and those with low baseline dietary calcium (five trials, 1582 women: RR 0.38, 95% CI 0.22 to 0.64).
There was also a reduction in the risk of pre-eclampsia with calcium supplementation (11 trials, 6894 women: RR 0.35, 95% CI 0.20 to 0.60). The effect was greatest in women at high risk of hypertension (five trials, 587 women: RR 0.22, 95% CI 0.12 to 0.42), and those with low baseline calcium intake (six trials, 1842 women: RR 0.29, 95% CI 0.16 to 0.54).
There was no overall effect on the risk of preterm delivery, although there was a reduction in risk amongst women at high risk of developing hypertension (four trials, 568 women: RR 0.45, 95% CI 0.24 to 0.83).
There was no evidence of any effect of calcium supplementation on stillbirth or death before discharge from hospital. There were fewer babies with birthweight, < 2500 g in women at high risk of hypertension (two trials, 449 women: RR 0.45, 95% CI 0.22 to 0.95).
In one study, childhood systolic blood pressure > 95th percentile was reduced (514 women: RR 0.59, 95% CI 0.39 to 0.91).
Authors' conclusions
Calcium supplementation appears to reduce the risk of high blood pressure in pregnancy, particularly for women at high risk of gestational hypertension and in communities with low-dietary calcium intake. Optimum dosage and the effect on more substantive outcomes requires further investigation.
P L A I N L A N G U A G E S U M M A R Y
Calcium supplements may prevent high blood pressure and help prevent preterm labour High blood pressure is a major cause of death in pregnant women and newborn babies worldwide. Preterm birth (birth before 37 weeks) is often caused by high blood pressure and is the leading cause of newborn deaths, particularly in low-income countries. The review of trials found that calcium supplementation during pregnancy is a safe and relatively cheap means of reducing the risk of high blood pressure in women at increased risk, and women from communities with low dietary calcium. No adverse effects have been found but further research is needed into the ideal dosage for supplementation and to confirm the above results, which are influenced by several rather small trials.
B A C K G R O U N D
High blood pressure with or without proteinuria are major causes of maternal death and morbidity worldwide (NHMRC 1993; HMSO 1994) , and perinatal morbidity and mortality. For this reason, strategies to reduce the risk of hypertensive disorders of pregnancy have received considerable attention (Carroli 1994; Bucher 1996; CLASP 1994; ECCPA 1996) .
Preterm birth, a common association with hypertensive disorders, is the leading cause of early neonatal death and infant mortality, particularly in low-income countries (Villar 1994) . Preterm survivors are at high risk of significant morbidity, especially respiratory disease and its sequelae, and long-term neurological morbidity (Johnson 1993) . Interventions to reduce preterm birth have been reviewed by Villar et al (Villar 1998) .
During early pregnancy, blood pressure normally falls, climbing slowly in later pregnancy to reach pre-pregnancy levels at term (Villar 1989) . These normal changes in blood pressure make the diagnosis of hypertension during pregnancy difficult. A widely accepted definition, however, is a diastolic blood pressure equal to or greater than 90 mmHg before the onset of labour, or an increase in systolic blood pressure of 30 mmHg or more, or in diastolic blood pressure of 15 mmHg or more. The consequences of high blood pressure are more serious if there is associated proteinuria. Hypertension and significant proteinuria (2+ by dipstick testing, equal to or greater than 300 mg per 24 hours, or equal to or greater than 500 mg per litre) usually indicate the presence of preeclampsia.
An inverse relationship between calcium intake and hypertensive disorders of pregnancy was first described in 1980 (Belizan 1980) . This was based on the observation that Mayan Indians in Guatemala, who traditionally soak their corn in lime before cooking, had a high calcium intake and a low incidence of preeclampsia and eclampsia. A very low prevalence of pre-eclampsia had been reported from Ethiopia where the diet, among other features, contained high levels of calcium (Hamlin 1962) . These observations were supported by other epidemiological and clinical studies (Hamlin 1952; Belizan 1988; Villar 1993; Villar 1987) , and led to the hypothesis that an increase in calcium intake during pregnancy might reduce the incidence of high blood pressure and pre-eclampsia among women with low calcium intake.
Low calcium intake may cause high blood pressure by stimulating either parathyroid hormone or renin release, thereby increasing intracellular calcium in vascular smooth muscle (Belizan 1988 ) and leading to vasoconstriction. A possible mode of action for calcium supplementation is that it reduces parathyroid release and intracellular calcium, and so reduces smooth muscle contractility. By a similar mechanism, calcium supplementation could also reduce uterine smooth muscle contractility and prevent preterm labour and delivery (Villar 1990) . Calcium might also have an indirect effect on smooth muscle function by increasing magnesium levels (Repke 1989) .
Calcium supplementation is attractive as a potential intervention to reduce the risk of a woman developing pre-eclampsia. Furthermore, the possibility of a protective effect on the risk of hypertension during childhood makes this even more attractive (Belizan 1997) . It is relatively cheap and readily available. Also, it is likely to be safe for the woman and her child, although this safety would need to be clearly demonstrated in pregnant women before any attempt at widespread introduction into clinical practice. A theoretical risk of increased renal tract stone formation has not been substantiated, and no other adverse effects of calcium supplementation have been documented.
This hypothesis was tested in several randomised trials commencing in the late 1980s which suggested a promising beneficial effect for calcium supplementation. The first systematic reviews highlighted the need for larger trials to assess the effects on important clinical outcomes in addition to pre-eclampsia and preterm delivery, such as perinatal mortality (Duley 1995; Carroli 1994) . A more recent systematic review (Bucher 1996) came to more enthusiastic conclusions, but this optimism was not confirmed by a large trial in the USA (CPEP 1997) .
There is thus a need for a systematic review of the current evidence concerning the effectiveness of calcium supplementation in pregnancy.
O B J E C T I V E S
To determine, from the best available evidence, the effect of calcium supplementation during pregnancy on the risk of high blood pressure and related maternal and fetal/neonatal adverse outcomes. Subgroup analyses will test whether these effects are influenced by whether:
(1) Women are at low/average risk of hypertensive disorders, or at high risk.
(2) Women have low or adequate dietary calcium intake prior to trial entry.
C R I T E R I A F O R C O N S I D E R I N G S T U D I E S F O R T H I S R E V I E W
Types of studies
All published, unpublished and ongoing trials with random allocation to calcium supplementation during pregnancy versus placebo (see 'Methods of the review'). Quasi-random designs will be excluded.
Types of participants
Pregnant women, regardless of the risk of hypertensive disorders of pregnancy. Women with diagnosed hypertensive disorders of pregnancy will be excluded.
Prespecified subgroups to be compared are:
(1) Women at low or average risk of hypertensive disorders of pregnancy (unselected).
(2) Women at above average risk of hypertensive disorders of pregnancy. These will include women selected by the trial authors on the basis of an increased risk of hypertensive disorders of pregnancy (eg teenagers, women with previous pre-eclampsia, women with increased sensitivity to angiotensin II, women with pre-existing hypertension).
(3) Women or populations with low baseline dietary calcium intake (as defined by trial authors, or if not defined, mean intake less than 900 mg per day). (4) Women or populations with adequate dietary calcium intake (as defined by trial authors, or if not defined, mean intake equal to or greater than 900 mg per day).
Types of intervention
Supplementation with calcium from at the latest 34 weeks of pregnancy; compared with placebo treatment. Studies with no placebo will be excluded.
The initial analysis will be limited to intended supplementation with at least 1 g of calcium per day. If there is evidence that this dose is beneficial, future updates of this review will include an analysis of effect by dosage, including lower dosage regimens.
Types of outcome measures
Prespecified clinical measures of maternal and fetal/neonatal morbidity and mortality will be sought as follows:
For the women (1) High blood pressure as defined by trial authors, with or without proteinuria. Ideally, high blood pressure would be defined as diastolic blood pressure equal to or greater than 90 mmHg, or an increase in systolic blood pressure of 30 mmHg or more, or in diastolic blood pressure of 15 mmHg or more.
(2) High blood pressure with significant proteinuria, as defined by trial authors. Ideally, proteinuria would be defined as 2+ by dipstick testing, equal to or greater than 300 mg per 24 hours, or equal to or greater than 500 mg per litre. Although the strict definition of preeclampsia includes confirmation of no hypertension or proteinuria outside pregnancy, for convenience the above definition will be referred to in this review as pre-eclampsia.
(3) Maternal death or serious morbidity (eg eclampsia; renal failure; syndrome of haemolysis, elevated liver enzymes and low platelets; admission to intensive care). (4) Placental abruption. (5) Cesarean section. (6) Mother's hospital stay seven days or more.
For the child (7) Preterm delivery (delivery before 37 weeks of estimated gestation). (8) Low birth weight (the first weight obtained after birth less than 2500 g). (9) Neonate small for gestational age as defined by trial authors. (10) Admission to neonatal intensive care unit (ICU). (11) Neonate in intensive care unit seven days or more. (12) Stillbirth or death before discharge from hospital.
Long-term outcomes
(13) Childhood disability. (14) Systolic blood pressure greater than 95th percentile during childhood. (15) Diastolic blood pressure greater than 95th percentile during childhood.
Only those outcomes with data will appear in the analysis table. The primary outcomes are outcomes 1, 2, 7, 10 and 12. Subgroup analyses will be limited to the primary outcomes.
S E A R C H M E T H O D S F O R I D E N T I F I C A T I O N O F S T U D I E S
See: methods used in reviews.
We searched the Cochrane Pregnancy and Childbirth Group trials register (September 2003) .
The Cochrane Pregnancy and Childbirth Group's trials register is maintained by the Trials Search Co-ordinator and contains trials identified from: 1. quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL); 2. monthly searches of MEDLINE; 3. handsearches of 30 journals and the proceedings of major conferences; 4. weekly current awareness search of a further 37 journals. Details of the search strategies for CENTRAL and MEDLINE, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the 'Search strategies for identification of studies' section within the editorial information about the Cochrane Pregnancy and Childbirth Group.
Trials identified through the searching activities described above are given a code (or codes) depending on the topic. The codes are linked to review topics. The Trials Search Co-ordinator searches the register for each review using these codes rather than keywords.
The Cochrane Central Register of Controlled Trials (The Cochrane Library, Issue 3, 2003) was also searched using the terms calcium AND pregnan* AND (hypertens* or blood press*).
Additional information obtained from the trialists and included in the previous version of this review (Duley 1995) for five studies (Belizan 1991; L-Jaramillo 1989; Villar 1987; Villar 1990; Marya 1987) was also included in this review.
M E T H O D S O F T H E R E V I E W
The methodological quality and other inclusion criteria of most identified trials were assessed independently by two reviewers who were not associated with any of the trials. Disagreements were resolved by consensus. The primary assessment for inclusion was based on concealment of allocation and whether the trial was placebo controlled.
Most data were independently extracted by two reviewers and cross-checked. Descriptive data included authors, year of publication, country, time span of the trial, maternal age, parity, type of placebo, baseline dietary calcium intake, type, dose, onset and duration of calcium supplementation, compliance, cointerventions, trial quality assessments, and number randomised and analysed. Double entry of data was used.
Categorical data were compared using relative risks and their 95% confidence intervals. Statistical heterogeneity between trials was tested for using the I-squared statistic, with values greater than 50% indicating significant heterogeneity. In the absence of significant heterogeneity, data were pooled using a fixed effects model. If there was significant heterogeneity, a random effects model was used and an attempt made to identify potential sources of heterogeneity (Greenland 1994; Villar 1995) based on subgroup analyses by risk of hypertensive disorders, baseline dietary calcium intake, trial quality and trial size.
For continuous data, pooled estimates of effect size were calculated from a weighted average, with weight based on the inverse of the variance (Early Breast Ca 1990). Comparisons, outcomes and subgroups other than those prespecified in the protocol are identified as 'post hoc' analyses.
D E S C R I P T I O N O F S T U D I E S
See table of 'Characteristics of included studies'. All included studies met the prestated criteria for inclusion in this review.
M E T H O D O L O G I C A L Q U A L I T Y
See table of 'Characteristics of included studies'. All were well designed, double-blind, placebo-controlled trials. Prespecified outcome data were not available from all trials. The possibility of reporting bias must be kept in mind for those outcomes with unreported data from some trials.
In Lopez-Jaramillo (L-Jaramillo 1990), a large discrepancy in numbers allocated to each group is not accounted for.
In some trials, individual denominators were not given for specific outcomes. Where it was clear that the outcomes were not measured in the entire group, we have adjusted the denominators accordingly.
In other respects, the methodology of the studies included appears sound.
R E S U L T S
Significant heterogeneity of results occurred for four outcomes: high blood pressure; pre-eclampsia; preterm delivery and birthweight less than 2500 g. Factors accounting for the heterogeneity appeared to be the predefined subgroups (by risk and baseline dietary calcium), and size of trial, with smaller effects in the larger trials. A random effects model has been used for these outcomes.
(1) High blood pressure with or without proteinuria Overall there is less high blood pressure with calcium supplementation (10 trials, 6634 women: relative risk (RR) random effects model 0.58, 95% confidence intervals (CI) 0.43 to 0.79), but there is variation in the magnitude of this effect across the subgroups. A funnel plot of relative risk against sample size shows asymmetry, with smaller effects in the larger trials (more than 1000 subjects). The magnitude of the effect was considerably greater amongst women at high risk of developing hypertension (four trials, 327 women: RR 0.47, 95% CI 0.22 to 0.97), and those with low baseline dietary calcium (five trials, 1582 women: RR 0.38, 95% CI 0.22 to 0.64).
(2) Pre-eclampsia The results follow a similar pattern to those for gestational hypertension. The overall effect was a reduction in the risk of preeclampsia (11 trials, 6894 women: RR 0.35, 95% CI 0.20 to 0.60). The effect was smallest in the largest trial which studied low risk women with adequate baseline calcium diet, and in whom the both groups received routine calcium supplementation (CPEP 1997) . The results are strongly influenced by the latter trial. The reduction is significant for women at low risk (six trials, 6307 women: RR 0.49, 95% CI 0.28 to 0.87), but not those with adequate calcium intake (four trials, 5022 women: RR 0.62, 95% CI 0.32 to 1.20). Pre-eclampsia was considerably reduced in women at high risk of hypertension (five trials, 587 women: RR 0.22, 95% CI 0.12 to 0.42), and those with low baseline calcium intake (six trials, 1842 women: RR 0.29, 95% CI 0.16 to 0.54).
(3) Maternal death or serious morbidity There were too few events for any meaningful conclusions.
(4) Placental abruption
There were too few events for any meaningful conclusions.
(5) Caesarean section
There was no statistically significant effect on the risk of caesarean section.
(6) Mother's hospital stay seven days or more Data were not available for this outcome.
(7) Preterm delivery
There was no overall effect, but preterm delivery did appear to be reduced among women at high risk of developing hypertension (four trials, 568 women: RR 0.45, 95% CI 0.24 to 0.83).
(8) Birthweight less than 2500 g
There were fewer babies with birthweight, less than 2500 g in women at high risk of hypertension (two trials, 449 women: RR 0.45, 95% CI 0.22 to 0.95), but this was a post hoc subgroup analysis.
(9) Neonate small for gestational age Data were not available for this outcome.
(10) Admission to neonatal intensive care unit
This outcome was reported in only three trials, and no effect was shown.
(11) Neonate in intensive care unit seven days or more Data were not available for this outcome.
(12) Stillbirth or death before discharge from hospital
No effect on this outcome was shown.
(13) Childhood disability
Data were not available for this outcome.
(14) Childhood systolic blood pressure greater than 95th percentile at about seven years of age was reduced (one trial, 514 women: RR 0.59, 95% CI 0.39 to 0.91) Data available from only one study. While the baseline calcium intake in the original study was low (calcium group mean 646 mg, standard deviation (SD) 396, placebo group 642, SD 448 in a sample assessed during the first four months of the study), the group followed up were only from among the 614 women from the private hospital, not the 580 from the public hospitals. Their dietary calcium intake may have differed from the mean (more likely to be higher in more affluent women). The baseline calcium status of the women in this part of the study therefore cannot be classified.
(15) Childhood diastolic blood pressure greater than 95th percentile Data only available from the study discussed above. The difference was not statistically different.
D I S C U S S I O N
Calcium supplementation was associated with: reduced hypertension in all subgroups (though the effect was modest for those at low risk); reduced pre-eclampsia, particularly for those at high risk and with low baseline dietary calcium intake (for those with adequate calcium intake the difference was not statistically significant); reduced preterm delivery and low birthweight for women at high risk of hypertension; and reduced childhood systolic hypertension in the one study to measure this outcome (low risk of hypertension and uncertain calcium intake). No side-effects of calcium supplementation have been recorded in the trials reviewed. There is little information about the long-term follow up of children within these trials (with the exception of blood pressure assessment in one trial), and there is no information about any possible changes in the use of healthcare resources associated with calcium supplementation. Reduction in the risk of hypertension and pre-eclampsia may be regarded as a meaningful outcome in itself. Women may be distressed by these diagnoses, and are commonly subjected to more interventions and hospitalisation (though the latter was not measured in the studies reviewed). There were, however, no documented differences in more substantive outcomes.
The heterogeneity of results is difficult to ascribe to a particular feature of the trials, as there is overlap between the classification of trials according to sample size, risk of hypertension and baseline dietary calcium intake. Most of the included trials employed sound methodology, being double-blind and placebo controlled. The potential for being misled by bias was thus small.
A U T H O R S ' C O N C L U S I O N S
Implications for practice
The lack of convincing evidence of effectiveness from the largest trial to date (CPEP 1997) may discourage the use of calcium supplementation. It should be borne in mind that the latter trial included women with a low risk of hypertension, adequate dietary calcium intake and, in addition, all women in both groups received low-dose calcium supplementation as part of their routine prenatal supplementation. Data from this trial are not necessarily applicable to the care of women who may be more likely to benefit from calcium supplementation.
The data included in this review support calcium supplementation for women at high risk of gestational hypertension, and in communities with low dietary calcium intake, provided that reduction in the diagnosis of hypertension or pre-eclampsia is regarded as important. Whether lower dosages of calcium than used in the trials reviewed may have similar effects, cannot be determined from this review.
Implications for research
Future research should focus on the ideal dosage for calcium supplementation during pregnancy. Further randomised trials should concentrate on women at high risk of gestational hypertension, and communities with low dietary calcium intake, and the effect on substantive outcomes should be determined. They should also include long-term follow up of the children and measures of the use of health service resources. The WHO multicentre randomised trial of calcium supplementation to prevent pre-eclampsia will address some of these issues (WHO).
P O T E N T I A L C O N F L I C T O F I N T E R E S T
Justus Hofmeyr is a collaborator in the WHO Calcium Trial (WHO) which will be considered for inclusion in this review. He will not participate in decisions regarding that trial.
A C K N O W L E D G E M E N T S
We thank the trial authors who have contributed additional data for this review, and Jose Villar for constructive criticism of the protocol.
S O U R C E S O F S U P P O R T
External sources of support
• UNDP/UNFPA/WHO/World Bank (HRP) SWITZER-LAND Compliance was 64% in the calcium group and 67% in the placebo group. 20% of women took > 90% of the allocated treatment.
Outcomes
Gestational hypertension (DBP sitting, fifth Korotkoff sound unless zero, 90 mmHg or more on 2 occasions, 4 hours-1 week apart); severe gestational hypertension (DBP 110 mmHg twice or treated, or complications); proteinuria (300 mg/24 hours or more, 1+ on 2 occasions 4 hours-1 week apart, 2+ or more, or protein/creatinine ratio 0.35 or more); pre-eclampsia (gestational hypertension + proteinuria within 7 days of each other); severe pre-eclampsia (50/2163 vs 59/2173); renal insufficiency (21/2163 vs 23/2173); urolithiasis (1/2163 vs 3/2173); prematurity (< 37 weeks); baby small for gestational age (124/2163 vs 105/2173); perinatal death.
Notes
Multicentre trial, 5 US university centres. Maternal outcomes reported as percentages of the whole number enrolled. In this review, denominators of 2,163 (calcium) and 2,173 (placebo) have been used. Neonatal outcomes in the report are based on live births (2134 and 2139). Addition of abortions and fetal deaths brings these numbers to 2156 and 2166. It is not clear why a discrepancy in numbers remains.
Allocation concealment A
Study Crowther 1999
Methods Central telephone randomisation, stratified by centre using variable blocks. Double blind.
Participants
Inclusion criteria: Nulliparous women; Singleton pregnancy; < 24 weeks' gestation; Blood pressure < 140/90 mmHg; expected to give birth at a collaborating centre. Exclusion criteria: antihypertensive therapy; medical contraindication to calcium supplementation.
Interventions
Calcium carbonate 1.8 g daily or lactose placebo tablets, from 20-24 weeks till birth.
Outcomes Primary: pregnancy-induced hypertension (diastolic blood pressure 90 mmHg or more on two consecutive occasions 4 hours apart, or 110 mmHg once; pre-eclampsia (as above plus proteinuria 0.3 g or more per 24 hours or 2+ protein or more on two random clean-catch urine samples); preterm birth (< 37 weeks). Secondary: severe pregnancy induced hypertension (diastolic blood pressure 110 or more on 2 occasions 4 hours apart, or 120 or more once); severe pre-eclampsia (as above plus proteinuria); very preterm birth (< 32 weeks; extremely preterm birth (< 28 weeks); maternal fetal and infant events after trial entry.
Notes
Five hospitals in Australia. August 1992 to December 1996. Estimated sample size 948. Trial stopped prematurely for financial reasons. 31% in the calcium group and 24% in the placebo group stopped taking the tablets during the trial. Analysis was by intention to treat.
Allocation concealment A
Study L-Jaramillo 1989
Methods Assigned independently in sequence using a 
Notes
Quito, Ecuador (altitude 2800 m). 1984 to 1986. An earlier report of apparently the same study gave an incidence of gestational hypertension of calcium 3/46 vs placebo 13/46 (Lopez-Jaramillo 1987).
Allocation concealment D
Study L-Jaramillo 1990
Methods Randomised, double-blind trial. Stated "Each patient was assigned independently in sequence", and "All women completed the study".
Participants
Healthy nulliparous women with positive roll-over test at 28-30 weeks' gestational age -judged at high risk for gestational hypertension.
Interventions 2,000 mg elemental calcium daily, from 28-32 weeks to delivery, vs placebo starch tablets.
Outcomes
Gestational hypertension (BP > 140/90 mmHg on 2 occasions 6 hours apart); proteinuria (300 mg/litre); duration of pregnancy (calcium mean 39.2 (SD 1.2) vs placebo 37.4 (2.3) weeks); birthweight (2936 (396) vs 2685 (427)g).
Notes
Quito, Ecuador (altitude 2800 m). Large discrepancy in size of groups not accounted for.
Allocation concealment B
Study L-Jaramillo 1997
Methods
Prospective, randomised, double-blind, placebo controlled trial. 14 withdrawals after randomisation: 12 by change to another hospital or private medical doctor, 2 by non-compliance. 9 /134 (6.7%) were from the calcium group and 5/140 (3.6%) from the placebo group.
Participants
Inclusion criteria: age < 17.5 years; nulliparous; first prenatal visit before 20 weeks' gestation; certain menstrual dates; residency in Quito for at least 1 year; BP =/< 120/80 mmHg; no underlying medical disorders; no drug, mineral or vitamin therapy. Average daily calcium intake in this population is 51% of the recommended dietary allowance.
Interventions
Elemental calcium 2 g daily as calcium carbonate from 20 weeks (n = 134), versus placebo tablets (n = 140).
Outcomes
Pre-eclampsia (BP > 140/90 mmHg on 2 occasions > 6 hours apart, and proteinuria > 300 mg/l (> 1+ on dipstick on 2 occasions 4-24 hours apart). BP recorded as mean of 2 measurements, 2 minutes apart, in the right arm, in the sitting position (1st and 5th Korotkoff sounds).
Maternal serum ionised calcium at 38 weeks was calcium group mean 1.23, SD 0.02 mM vs placebo 1.16, 0.02; umbilical cord serum ionised calcium levels were calcium 1.44, 0.04 vs placebo 1,37, 0.03; gestational length was calcium 39.6, 0.4 versus placebo 38.7, 0.3.
Notes
Quito, Ecuador (altitude 2800 m). 1990 to 1995.
Allocation concealment A
Study Niromanesh 2001
Methods Double-blind, placebo controlled clinical trial. Women were "andomly assigned".
Participants
Women at high risk for pre-eclampsia: positive 'roll-over' test and at least on risk factor for pre-eclampsia; 28-32 weeks' pregnant; blood pressure < 140/90 mmHg. Exclusion criteria: chronic medical conditions. Not defined as low-or adequate calcium intake.
Interventions
Elemental calcium 2 g daily (500 mg 6-hourly) or placebo, coded by the pharmacy.
Outcomes
Pre-eclampsia: an increase (30 mmHg) of systolic blood pressure above 14 mmHg and an increase (15 mmHg) of diastolic blood pressure above 90 mmHg, twice 4-6 hours apart, with proteinuria 1+; duration of pregnancy (39.5 SD 0.8 vs 37.7 SD 2.5 weeks); birthweight (3316 SD 308 vs 2764 SD 761 grams); weekly maternal weight increase (no difference).
Notes
No loss to follow up.
Allocation concealment A
Study Purwar 1996
Methods Prospective, randomised, double-blind, placebo-controlled trial. Allocated by means of a computer-generated randomisation list. After randomisation, 11/201 (5.5%) women lost to follow up (calcium 6, placebo 5).
Participants
Calcium intake mean 336 mg (calcium) and 352 mg (placebo group) per day. Inclusion criteria: nulliparity; normal single viable pregnancy; known dates; antenatal clinic before 20 weeks; intending to deliver in the same institute; normal glucose tolerance test; no hypertension; no underlying medical disorders.
Exclusion criteria: renal disease; collagen vascular disease; chronic hypertension; endocrinological disease; taking medication.
Interventions
Oral calcium containing 2 g elemental calcium daily (n = 103), compared with identical placebo tablets (n = 98), taken from 20 weeks.
Outcomes
Gestational hypertension (SBP > 140 mmHg and DBP > 90 mmHg, twice 6 hours apart) and pre-eclampsia (hypertension + proteinuria =/> 0.3 g/24 hours).
Notes Nagpur, India. 
Allocation concealment A
Study Villar 1990
Methods Double-blind, randomised trial. Allocation by opaque envelopes, ordered by a computer-generated list of random numbers.
Participants
Pregnant women 17 years or younger; no underlying medical disorders; most were nulliparous with known last menstrual period and singleton pregnancy.
Interventions 2 g elemental calcium as 500 mg calcium carbonate tablets, vs placebo tablets. All women were prescribed prenatal vitamin tablets containing 200 mg calcium and 100 mg magnesium per day.
Outcomes
Preterm labour; preterm delivery (< 37 weeks); delivery 30 -37 weeks; idiopathic prematurity; spontaneous prematurity; low birthweight (< 2500 g); postdates > 42 weeks (calcium 7.4 vs placebo 5.3%); impaired fetal growth (3.2 vs 3.2%); premature rupture of membranes (2.1 vs 1.0%); Apgar score < 8 at 5 minutes (4.4 vs 10.5%). Participants: healthy, 20-35 years, singleton pregnancy. Intervention: calcium 1 g (n = 11), calcium 2 g (n = 11) or placebo (n = 14). Outcomes: DBP 20-24 weeks, and in the third trimester. Study design: randomised, no further information.
Notes
Boggess 1997 N = 23. After randomisation, 5/23 (22%) were excluded. 
Felix 1991
Excluded as allocation was by alternation, not random. 14 women received calcium supplementation and 11 received placebo. No women developed hypertension or pre-eclampsia. The production of 6-keto-prostaglandin F1alpha by umbilical arteries was similar between groups.
Herrera 1998
Excluded because the intervention was a combination of calcium and linoleic acid. Kawasaki 1985 N = 94. Not a randomised trial.
Interventions: calcium L-aspartate 600 mg/day from 20 weeks to delivery (n = 22) vs no supplementation (n = 72). Outcomes: pregnancy-induced hypertension.
Knight 1992
Excluded because no clinically relevant outcomes reported, placebo not used, and subjects not followed till delivery. Normotensive (n = 30 and hypertensive (BP 140/85 mmHg or more, n = 20) nulliparous women "randomly allocated" to receive calcium 1 gram from about 12 weeks to 32 weeks, or a control group. Follow up continued to 36 weeks. Mean diastolic blood pressure reduced in the hypertensive group receiving calcium.
Lavin 1986
Planned trial of calcium versus placebo in women with a positive roll-over test at 28-32 weeks. Trial apparently cancelled. Marya 1987 N = 400. The method for allocating women to the two groups was not clear from the report. Additional information obtained from the first author indicated that alternate allocation was used.
Interventions: calcium 375 mg per day plus vitamin D 1200 IU per day from 20-24 weeks onward, and no supplementation. Outcomes: 'toxaemia'. Montanaro 1990 N = 170. No placebo.
Participants: normotensive at 24 weeks' pregnancy. Interventions: calcium 2 g/day from 24 weeks to delivery. Outcomes: pregnancy induced hypertension, pre-eclampsia. Study design: "randomised, single-blinded trial".
Raman 1978 N = 273. Allocation was by strict rotation, a quasi-randomised trial. Supplementation with < 1 g/day.
Repke 1989 N = 255. Presented as abstract only. No clinical data available.
Interventions: calcium 2 g/day vs placebo, after 20 weeks of pregnancy. Study design: 'randomised clinical trial'.
Rogers 1999
Excluded because: (1) randomisation performed "using five unsealed envelopes"; unequal group numbers suggested that 'something went wrong with the randomisation process'; (2) no placebo used; (3) initial calcium dose 600 mg per day (1200 mg per day after 32 weeks); (4) 10% loss to follow up.
Hypertension alone occurred in 21/144 women who received calcium compared with 18/75 controls; pre-eclampsia in 8/144 vs 7/75 respectively. S-Ramos 1995 N = 75. Excluded because calcium used for treatment of women with pre-eclampsia rather than prevention.
Participants: nulliparous, gestation 24-36 weeks; mild pre-eclampsia (BP 140/90-160/100, proteinuria at least 300 mg/day). Interventions: calcium 2 g/day elemental calcium (four tablets of calcium carbonate 1250 mg), versus matching placebo. Outcomes: initial and last BP and biochemical markers; preterm delivery; caesarean section; severe pre-eclampsia; gestation at delivery; birthweight; Apgar < 7 at 1 minute and 5 minutes; cord arterial pH < 7.16; fetal growth restriction; perinatal death. Study design: double-blind, placebo-controlled study using a computer-generated random number list.
Suzuki 1996 N = 152. Not a randomised trial.
Interventions: calcium 1 g/ day from 20 weeks vs no calcium. Outcomes: pre-eclampsia, gestational hypertension.
Tamas 1997
Study of treatment of gestational hypertension, not prevention, using the drug dobesilate calcium, not calcium supplementation.
Characteristics of excluded studies (Continued )
Wanchu 2001 No placebo used. 120 consecutive nulliparous women less than 20 weeks pregnant "randomly assigned" to receive 2 g elemental calcium daily, or no treatment. Analysis restricted to 100 women who "completed the protocol". Mild pre-eclampsia occurred in 9/50 vs 6/50 and severe pre-eclampsia in 0/50 vs 2/50 study vs control groups respectively.
BP: blood pressure DBP: diastolic blood pressure IU: international unit vs: versus
Characteristics of ongoing studies
Study Mahomed 1998
Trial name or title Calcium supplementation for the prevention of pregnancy induced hypertension and preterm labour in twin pregnancies: a randomised controlled trial.
Participants
Women with twin pregnancy.
Interventions
Calcium solution (1 g elemental calcium per 5 ml).
Outcomes
Pregnancy-induced hypertension, preterm labour, perinatal mortality and short-term morbidity, maternal morbidity.
Starting date Not stated.
Contact information Prof K Mahomed. Notes
Sample size 400 per group.
Study WHO
Trial name or title WHO multicentre randomised trial of calcium supplementation for the prevention of pre-eclampsia.
Participants
Nulliparous, normotensive women who are less than 20 weeks pregnant at enrolment. 
Interventions
Date new studies sought but none found
Information not supplied by author
Date new studies found but not yet included/excluded
Date new studies found and included/excluded
G R A P H S A N D O T H E R T A B L E S Analysis 01.01. Comparison 01 Routine calcium supplementation in pregnancy by hypertension risk, Outcome 01 High blood pressure (with or without proteinuria)
Review: Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems 
